Absolute Bioavailability of BI 1265162 Following Oral and Inhaled Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study Followed by a Fixed Treatment)
Latest Information Update: 08 Jul 2022
At a glance
- Drugs BI 1265162 (Primary) ; BI 1265162 (Primary) ; BI 1265162 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 15 Jan 2020 Status changed from active, no longer recruiting to completed.
- 23 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 28 May 2019 Planned End Date changed from 17 Jun 2019 to 6 Dec 2019.